Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Tolerability of Adezunap in Chronic Back Pain
NCT06072560Phase 3Recruiting
- Sponsor
- Apurano Pharmaceuticals GmbH
- Start
- Nov 2023
- Primary completion
- Sep 2024
- Modality
- Small Molecules, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic back pain comparing Adezunap (AP707) with Placebo (2 arms). Primary endpoint: Change in pain level on the Numeric Rating Scale at 14 weeks. Started Nov 2023; status: recruiting.
02
Drugs
adezunap
03
Conditions
chronic back pain
Beyond the preview
Go deeper on NCT06072560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06072560.